1. Lilly says its monoclonal antibody prevented COVID-19 infections in trial — Roche gets priority review on blockbuster IPF drug — California says batch of Moderna vaccine is safe, despite reports of illnesses — See more on our front page news Stay updated with the latest pharma-related coronavirus news on our new page
    Dismiss Notice

Today’s Conference call

Discussion in 'Aerie Pharma' started by anonymous, Aug 24, 2018 at 11:56 AM.

Tags: Add Tags
  1. anonymous

    anonymous Guest

    To the leadership team,

    How did you make such high forecasts with no managed care? The Medicare PAs that get approved are $150-200. Let’s promote Rhopressa 2nd line when the PAs require 3rd or 4 failures.... genius!
     

  2. anonymous

    anonymous Guest

    The culture here is amazing. The call was very motivational, thank you Judy for being bumbling idiot. Gary, great job! It’s been 3 months. Does this company think this drug is changing glaucoma? It’s not. If used early maybe, we don’t have coverage bottom line and payers won’t cover it they cover it 3rd or 4th line. Whoever forecast, should be fired... and what startup goes public so early? The people running the company clearly don’t get it. They don’t understand the market. How dare you shame us on this call. Saying you are disappointed in our results? Judy, keep bumbling your uneducated words. I’ll forecast a mass exitous.

    btw... rocklatan will never get covered! So whoever’s forecasting or dreaming, or just plain stupid. Stop it. Forecast low. No one is going to cover this drug.
     
  3. anonymous

    anonymous Guest

     
  4. anonymous

    anonymous Guest

    Of course management is reading this and so are the shareholders and stock analysts but who cares.
    Get crack'n on your 10 calls per day. That's really gonna turn the tide.
    When in doubt, do the reach and frequency dog and pony show.
    Seeing some ECP's twice a week or more.
    Keep saying the same thing over and over like a parrot until the ecp tosses you out of their office and hands you back your samples.
    What's the big deal doc? Divert costly employee resources from more important office work to do PA's for Rhopressa. You'll be glad you did. Especially when the co-pays come back at $80.
    Where are all those samples going?
    One sample/One script doc - or else!
    Doc, get that patient off of brimonidine.
    I don't care if they're tolerating it and their IOP is stable, gosh darn it!
    You have to switch them to Rhopressa because our management needs to make more money.
    Put that in the PA as financially necessary!
     
  5. anonymous

    anonymous Guest

    This place is ran by a bunch of misfits... total joke. Getting out of here ASAP.
     
  6. anonymous

    anonymous Guest

    If it's this bad so early on in the game, nothing good is going to come of it.
    Probably best to start looking.
     
  7. anonymous

    anonymous Guest

    If I wasn’t already disillusioned enough by the fear and intimidation tactics by my manager this conference call did the trick. What they don’t get is is they hired a bunch of seasoned reps with good relationships and they’re ruining their reputation as we speak. If they want to succeed they better start treating the people representing their company with some respect.
     
  8. anonymous

    anonymous Guest

    If the goal of that call was to get an entire district looking for their next job, they succeeded on my team. The people running the show here are NUTS. Can't wait to get out of here
     
  9. anonymous

    anonymous Guest

    Worst launch ever. All driven by upper management’s desire to protect their investment. It’s disappointing for sure -can’t wait to get out of here. And I will for sure be telling ALL my Drs and KOL’s why I left so soon.
     
  10. anonymous

    anonymous Guest

    Good to know I’m not the only one who thinks the way we’re being treated is insane. I’ve never been treated so poorly or this micro-managed. And I have decent numbers! I feel sorry for people who don’t...as we know it’s all about coverage. I can’t even take the credit as I also have some early adopters and speakers. As Gary said on the CC - “we need to change” Truer words have never been spoken. I am definitely going to make the change! This place is AWFUL
     
  11. anonymous

    anonymous Guest

    Management is worried first and foremost about the stock price. Not about providing value to ECP’s and their patients.

    If they think arm twisting tactics are going to bring more sales and drive the stock price up, I gotta bridge in Brooklyn for sale.

    This is a pyramid scheme pure & simple. The folks at the top want to take their money & run.

    We’re just pawns to use until we are no longer useful. Then “employee at will” kicks in.

    Check this out.
    Aerie Pharmaceuticals Inc (NASDAQ:AERI) insider Casey C. Kopczynski sold 11,000 shares of the stock in a transaction on Wednesday, August 1st. The stock was sold at an average price of $68.30, for a total transaction of $751,300.00. Following the sale, the insider now owns 163,307 shares of the company’s stock, valued at approximately $11,153,868.10. The sale was disclosed in a filing with the SEC, which is available through the SEC website.”

    Go see how many shares he sold and how much he made in May.

    And they want to screw us on bonus?

    F them!!!
     
  12. anonymous

    anonymous Guest

    Does everyone’s goals seemed to be the same evenly spread across districts/reps?
     
  13. anonymous

    anonymous Guest

    After reading these latest comments, I’m glad I laughed at their pathetically low offer. Too bad for those who thought there was potential with these rookies running the place.
     
  14. anonymous

    anonymous Guest

    No! It’s the same for everyone. At least the reps I’ve talked to. And it’s not going to happen.
     
  15. anonymous

    anonymous Guest

    We are the best of the best. They interviewed about 3,000 candidates and picked us because we were the best. Well, now we're gonna be the best darn toot'n primary care reps the industry has ever seen!

    Thank You Aerie!

    P.S. We should stop our sulking. We're overpaid according them, anyways.
     
  16. anonymous

    anonymous Guest



    That's funny! Best of the best! LOL. Aerie hired the fired/laid off, worst of AGN and any other company that got rid of the dead weight. Aerie hired regional managers with mediocre sales ability. The manager I interviewed with was pathetic.
     
  17. anonymous

    anonymous Guest

    We are behind projected Rxs but never gave you goals. We launched 4 months ago with no historical data to base goals on but now you found the data to have some unattainable goal within a short period of time! My previous glaucoma portfolio goal was not even that high! Where the hell do these numbers come from... come on!
     
  18. anonymous

    anonymous Guest

    Yeah... That's hilarious...I worked with one of the girls Aerie hired... She sold Glaucoma drugs for over 10 years, but never detailed them -instead giving the same "Dry eye" message to every doc, and she was nearly dead last in ranking before she was laid off... But, hey, she's pretty, sweet, and perky, so I guess that qualifies as "Best of the best"..
     
  19. anonymous

    anonymous Guest


    The CFO that forecasted this ridiculous number should find a new job. How can Aerie be so wreckless and let a complete moron forecast so high? How can you lie to the investors... I hope they are reading this! We have zero coverage and you expect that crazy amount of rxs?!? This is hilarious. Good luck!
     
  20. anonymous

    anonymous Guest

    Hook line and sinker.